Chargement en cours...
Inotuzumab Ozogamicin in Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
Despite initial complete remission rates of up to 90%, long-term, disease-free survival remains poor in patients with newly diagnosed acute lymphoblastic leukemia (ALL). Response to salvage chemotherapy is suboptimal; therefore, novel therapeutic agents are being investigated in order to improve out...
Enregistré dans:
| Publié dans: | J Adv Pract Oncol |
|---|---|
| Auteurs principaux: | , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Harborside Press
2018
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6505665/ https://ncbi.nlm.nih.gov/pubmed/31186988 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|